ALPHAPORT.AI
🇹🇼GeneFerm1796
TWDUSD
SectorConsumer StaplesIndustryFoodWebsitehttp://www.geneferm.com
Management
金晉德
CEO

Company information

Ticker
1796
Country
Taiwan
Sector
Consumer Staples
Industry
Food

GeneFerm Business Summary

GeneFerm Biotechnology Co., Ltd. (1796.TWO) is a premier Taiwan-based specialist in microbial fermentation and extraction, operating primarily through a high-yield Contract Development and Manufacturing Organization (CDMO) model. The company generates revenue by providing end-to-end services for the global health and nutrition industries, including microbial fermentation toll manufacturing, raw material extraction, and private-label supplement development (OEM/ODM). Its primary business segments are categorized into Functional Ingredients—featuring flagship products like NattoMena® (Vitamin K2), TestoPro® probiotics, and nattokinase—and comprehensive CDMO services that leverage its large-scale fermentation facilities in Tainan and Xinying. GeneFerm competes directly with regional players such as Jia Jie Biomedical (4109), G&E Herbal Biotechnology (4911), and Dv Biomed (6539), as well as global giants like DSM and Kappa Bioscience. Within this landscape, GeneFerm distinguishes itself through a structural pricing advantage in the Asian market derived from its proprietary ActiConvert and fermentation-based manufacturing efficiencies. Founded in 1999 by Jin Wei-Min, a veteran with over 30 years of expertise in microbial activities, the company is currently led by Chairman Chang Hsiao-Li and General Manager Jin Jin-De, who oversees the firm’s strategic expansion into precision fermentation. The executive team is bolstered by Vice General Manager and Spokesperson Frank Hsiao, who manages international collaboration and investor relations. The company’s technical pedigree is anchored in its R&D team’s success in securing numerous international patents and gold medals at global innovation competitions, such as the IIIC. GeneFerm’s governance is supported by a board that includes independent directors Fang-Tsai Chiu and Tsung-Min Chen, and the company has attracted institutional backing from notable investors such as Vincera Capital, reflecting its established position as a critical upstream supplier in the biotechnology and functional food processing sectors.

Updated 2026-07-29 · TW Taiwan public company filings
Financial Metric TrendsQuarterly⌄
Business Overview is available publicly. Financials, KPIs, reports, transcripts and the rest of Research require the Research tier.